Cognition Therapeutics Completes Phase 2 Enrollment of Zervimesine in Early Alzheimer's Disease Study

Cognition Therapeutics has completed enrollment in its Phase 2 study of zervimesine (CT1812) in early Alzheimer's disease, with 540 participants and additional patients in the final stages of screening. The study aims to assess the safety and activity of the drug in participants with mild cognitive impairment or early Alzheimer's disease. Topline results are expected after 18 months of treatment, and the drug has the potential to be an important part of Alzheimer's treatment due to its oral dosing and safety profile.